azd8055

AZD8055 is a potent, selective, orally bioavailable small molecule inhibitor of the mammalian target of rapamycin (mTOR) kinase. It targets both mTOR complex 1 (mTORC1; rapamycin-sensitive) and mTOR complex 2 (mTORC2; rapamycin-insensitive), acting as an ATP competitive inhibitor with high specificity for mTOR over other kinases. By inhibiting the serine/threonine kinase activity of mTOR, AZD8055 blocks phosphorylation of downstream effectors such as S6K1 and AKT, leading to decreased protein synthesis, cell cycle arrest, and induction of apoptosis in tumor cells. The drug has demonstrated antitumor activity in preclinical models and has been evaluated in early-phase clinical trials for various cancers including solid tumors and lymphomas[1][4][6][7].

Other names

(5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol